Evaluation and Management of Elevated Liver Function Tests
Initial Laboratory Assessment
- The American Association for the Study of Liver Diseases recommends performing a complete blood count with differential and platelets, comprehensive metabolic panel, hepatitis B surface antigen, and hepatitis C antibody to identify the underlying cause of elevated liver function tests 1, 2, 3
- The European Association for the Study of the Liver suggests including fasting lipid panel, fasting glucose, HbA1c, ferritin, and transferrin saturation in the initial laboratory assessment 2
- Autoimmune markers such as ANA, ASMA, anti-LKM, and immunoglobulins should be measured if clinically indicated 1
Pattern Recognition and Risk Stratification
- The American College of Gastroenterology recommends classifying the pattern of elevation as hepatocellular or cholestatic based on the R-ratio (where R = [ALT/ULN] ÷ [ALP/ULN]) 4
- The American Association for the Study of Liver Diseases suggests calculating the FIB-4 or NAFLD Fibrosis Score (NFS) to stratify fibrosis risk in patients with metabolic risk factors and other causes excluded 1, 5, 2
- A FIB-4 score of <1.3 (or <2.0 if age >65) indicates low risk of advanced fibrosis, while a score of >2.67 (or >3.25 if age >65) indicates high risk of advanced fibrosis 5, 6
Imaging Studies
- The American College of Radiology recommends obtaining a right upper quadrant ultrasound to assess for hepatic steatosis, evaluate the biliary tree for obstruction, and screen for hepatocellular carcinoma if cirrhosis is suspected 2, 1
Medication and Supplement Review
- The National Institute of Diabetes and Digestive and Kidney Diseases suggests critically reviewing all medications, over-the-counter drugs, herbal supplements, and biotin-containing products to identify potential hepatotoxic agents 4
- The American Association for the Study of Liver Diseases recommends discontinuing hepatotoxic agents immediately if ALT/AST >5× ULN or any elevation with jaundice 4